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Background: Data collection for economic evaluation alongside clinical trials is burdensome and cost-intensive.
Limiting both the frequency of data collection and recall periods can solve the problem. As a consequence, gaps in
survey periods arise and must be filled appropriately. The aims of our study are to assess the validity of incomplete
cost data collection and define suitable resource categories.
Methods: In the randomised KORINNA study, cost data from 234 elderly patients were collected quarterly over a
1-year period. Different strategies for incomplete data collection were compared with complete data collection. The
sample size calculation was modified in response to elasticity of variance.
Results: Resource categories suitable for incomplete data collection were physiotherapy, ambulatory clinic in
hospital, medication, consultations, outpatient nursing service and paid household help.
Cost estimation from complete and incomplete data collection showed no difference when omitting information
from one quarter. When omitting information from two quarters, costs were underestimated by 3.9% to 4.6%.
With respect to the observed increased standard deviation, a larger sample size would be required, increased by
3%. Nevertheless, more time was saved than extra time would be required for additional patients.
Conclusion: Cost data can be collected efficiently by reducing the frequency of data collection. This can be
achieved by incomplete data collection for shortened periods or complete data collection by extending recall
windows. In our analysis, cost estimates per year for ambulatory healthcare and non-healthcare services in terms of
three data collections was as valid and accurate as a four complete data collections. In contrast, data on
hospitalisation, rehabilitation stays and care insurance benefits should be collected for the entire target period,
using extended recall windows. When applying the method of incomplete data collection, sample size calculation
has to be modified because of the increased standard deviation. This approach is suitable to enable economic
evaluation with lower costs to both study participants and investigators.
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Economic evaluation alongside clinical trials is gaining
importance because of demographic trends towards
an ageing population, which is a relevant driver for
resource use in healthcare [1-3]. There are different
types of data that can be used to collect information
on healthcare costs: reviewing medical charts or admin-
istrative data sets; drawing on experts’ experiences
of healthcare utilisation; and gathering patients’ self-
reported resource use [4]. Patients’ self-reported
resource use can be recorded prospectively with cost
diaries or retrospectively by means of questionnaires.
However, cost data collection in clinical trials can be
burdensome and can increase both the costs of clinical
trials [5] and the burden on study participants [6] and
clinical investigators [7].
For economic evaluation from a societal perspective,
only patients’ self-reported resource use offers an ac-
count of out-of-pocket payments (e.g. paid household
help or over-the-counter medications). Cost data collec-
tion from health insurance companies is complex be-
cause patients are enrolled in different insurance funds,
which is true in Germany and also in the USA. Hence,
prospective or retrospective methods based on patient
recall are widely used [8-10].
Retrospective assessment of costs via questionnaires
raises the question of how often participants should be
contacted and what is the appropriate recall time frame
[11,12]. Recall ability declines with age, the frequency
of resource use and the length of the recall time frame
[9]. If patients are asked more frequently, recall bias is
minimised, but the cost of data collection and the bur-
den on study participants are increased [13]. For the
prospective assessment of costs via cost diaries, the
period covered by each diary and the frequency with
which the diaries are sent back needs to be defined. For
long-term clinical trials, e.g. 12 months or longer, the
burden on study participants of keeping the diary is sub-
stantial and it is unlikely that participants will complete
all the diaries [14].
With regard to the above-mentioned problems, an al-
ternative approach to minimise recall bias and the fre-
quency of questioning is to limit the time period
covered by each diary or to limit the recall period [15].
As a consequence, gaps in survey periods arise and must
be filled appropriately by the collected data. This ap-
proach has already been used to collect cost data in both
cross-sectional studies and randomised controlled trials.
In a cross-sectional study on healthcare costs in the eld-
erly, Heinrich et al. assessed resource use over various
time spans and extrapolated the data to annual costs by
assuming that the documented resource use over abbre-
viated periods would also be found over a 12-month
period [16]. In the randomised controlled trial on thecost-utility of psychological treatment for depression
and anxiety, Hakkaart-van Roijen et al. [17] interviewed
patients every 3 months over a period of 1.5 years asking
for medical resource use over the past 4 weeks. They
extrapolated the documented resource use by assuming
that 4 weeks was representative of the total period of
3 months. Kimman et al. [18] conducted an economic
evaluation alongside the randomised controlled trial on
treatment for breast cancer, collecting cost data after 3,
6 and 12 months for a period of 4 weeks to interpolate
them by assuming that 4 weeks was representative of the
in-between periods.
Goossens et al. [14] investigated whether there is a dif-
ference in costs between data from limited time periods
extrapolated to 1 year and cost diary data from the en-
tire year. They could not find any significant difference
between the cost data in the alternative periods. Clarke
et al. [13] published a statistical framework specifying
cases for which the recall period can be limited by trad-
ing off recall bias against information loss.
Considering the importance of limiting the recall
period or the period covered by each diary in favour of
reduced time and effort for both participants and inves-
tigators, there is still little empirical evidence regarding
the validity of cost collection with gaps in survey periods
in long-term clinical trials. For this purpose, we com-
pared the impact of different gaps in survey periods on
the validity of cost measurement in the relevant health-
care service categories using data from a randomised
controlled trial.
The main objective of our paper is to assess the valid-
ity of incomplete cost data collection concerning the
precision and accuracy of cost estimates. Two further
objectives are to identify the healthcare service categor-
ies suitable or not suitable for inter-/extrapolating in-
completely collected cost data and to demonstrate the
consequences of collecting data for an abbreviated time
period on sample size calculation with respect to chan-
ging the variance of the estimate.
Methods
Study design and study population
The data used were obtained from the randomised con-
trolled KORINNA trial (Koronarinfarkt-Nachbehan-
dlung im Alter), which is an ongoing monocentre study
at the Central Hospital of Augsburg, Germany, to evalu-
ate the cost-effectiveness of a case management inter-
vention by trained nurses in elderly patients (≥ 65 years)
with acute myocardial infarction. The control group
received usual care. The primary goal of the KORINNA
study is to assess whether case management can reduce
readmission or out-of-hospital death. As a secondary ob-
jective, the incremental cost-utility ratio of this case
management intervention will be estimated. The
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study protocol, which was approved by the Ethics
Committee of the Bavarian Chamber of Physicians,
describes the intervention in more detail and is pub-
lished elsewhere [19]. The trial registration number is
ISRCTN02893746. Between September 2008 and May
2010, 340 patients from the Augsburg region were en-
rolled. For this analysis, cost data for 234 patients with
complete 1 year follow-up (quarters one, two, three
and four) were available. The mean age of participants
was 75 years, and nearly 38% (n=88) were women.
Cost measurement
Cost measurement by bottom-up gross costing [20] is a
two-step process. First, duration and/or frequency of
resources used by patients were collected via a
questionnaire-based interview. Second, unit prices are
determined and multiplied by duration and/or frequency
of resource use.
Cost measurement was performed from the societal
perspective, which includes both direct healthcare costs
and direct non-healthcare costs. Indirect costs are not
considered in this analysis, as all participants were
already retired and did not incur production loss due to
illness-related absence from work. Data collection was
not limited to disease-related services and protocol-
driven costs were factored out [19,21].
Collection of resource use
Over a 1-year period, participants were interviewed
quarterly regarding the previous time period of 3 months,
either by computer-assisted telephone interview (CATI)
or in a face-to-face interview. In the case of CATI,
plausibility checks were included and, in the case of
face-to-face interviews, double data entry was applied.
Data evaluation and necessary adjustments were per-
formed as described below.
Direct healthcare use For costs incurred for outpatient
and inpatient care, the number of visits to a general
practitioner, specialist care, ambulatory clinics in hos-
pital and physiotherapy, days spent in hospitals, inten-
sive care units and rehabilitation were documented.
Medication administered at the time of the survey was
recorded by IDOM software, a database-supported iden-
tification system that logs the name, units, pharmaceut-
ical identification number, time period, package size and
price per package [22]. In certain cases, medication data
had to be adjusted to calculate the cost of medication
properly and this is described as follows. For some medi-
cations – such as insulin – package size was converted
from millilitres or prefilled pens/syringes to international
units. Similar problems arose in the case of drops, inha-
lants and aerosols. In these cases, the numbers of dropsor puffs per package had to be calculated based on infor-
mation from the pharmaceutical company because the
units per package disagree with the units of medication
administration. If patients ingested antibacterials or
subcutaneously administered anticoagulants, it was
assumed that one package of the medication was bought.
Medications not taken regularly were not included in
the analysis.
Direct non-healthcare use Costs incurred for formal
care and home help were documented as days per week
and hours per day of outpatient nursing service and paid
household help. The level of care needs, as assessed
by the medical services of the long-term care insurance
fund, served as a proxy for the extent of informal
care [23].
Unit prices for resource use
Unit price calculation for resource use was primarily
based on the methods published by Krauth et al. [24]. All
unit prices were reported for the year 2008. Table 1 gives
an overview of prices assigned to the resource quantities.
The costs of physicians, published as weighted average
values of patient-physician contact for privately and
statutorily insured patients, [24] were updated concern-
ing the reimbursement from the Statutory Health Insur-
ance (SHI) per case, drawing on data from the National
Association of Statutory Health Insurance Physicians
[25]. The weighted costs per contact with physiothera-
pists (€13.75) were calculated from data from the SHI
contract for the supply of remedies [26] and the stipula-
tion of allowance for civil servants [27]. Costs of ambu-
latory clinics in hospital were calculated by the average
reimbursement from the Augsburg hospital (€40.31).
The price per hospital day (€511.07) was based on Fed-
eral Statistical Office [28] and National Health Report
data [29], using Krauth’s [24] calculation method. The
latest published price of intensive care units from 2003
[30] was extrapolated to 2008 using the yearly inflation
rate of hospital costs [29] (€1,199.14). Inpatient rehabili-
tation (€100 per day) and outpatient rehabilitation
(€1535 per case) were based on data from the pension
insurance companies [31]. The prices of medications
were based on the medication database of the scientific
institute of the statutory sickness funds in Germany
(WIDO) [32]. The total drug costs were computed by
calculating cost per dose and multiplying by the fre-
quency and duration of administration. Costs per hour
of outpatient nursing service (€28.30) and paid house-
hold help (€15.70) were valued based on the contract be-
tween the associations of nursing caregivers and the
Local Health Care Fund [33]. Informal care was valued
according to the benefits received per nursing care level,
which is granted by the German Long Term Care
Table 1 Unit prices (all unit prices are expressed in euros
at 2008 values)





General practitioner 20.65 per contact
Internist 44.44 per contact
Orthopaedist 27.92 per contact
Neurologist 18.30 per contact
Ophthalmologist 31.17 per contact
Otolaryngologist 29.64 per contact
Gynaecologist 32.03 per contact
Dermatologist 18.62 per contact
Urologist 34.41 per contact
Other 27.43 per contact
Physiotherapist 13.75 per contact
Ambulatory clinic in hospital 40.31 per contact
Inpatient care/hospital 511.07 per day
Inpatient care/intensive care unit 1199.14 per day
Inpatient rehabilitation 100.00 per day
Outpatient rehabilitation 1535.00 per stay
Drugs various quantity - according
to medication
Direct non-healthcare
Outpatient nursing service 28.30 per hour
Paid household help 15.70 per hour
Informal care
care level
none 0 per month
1 215.00 per month
2 420.00 per month
3 675.00 per month
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care [23]. The benefit is a transfer payment to patients,
who do not engage outpatient nursing services but also
need help in activities of daily living (ADL), e.g. eating,
bathing, dressing, and/or in instrumental activities of
daily living (IADL), e.g. housework, cooking, shopping.
The benefit level is determined by nursing care level
and, although it is a transfer payment, it is used here as
a proxy value for informal care.
Dealing with missing data
As only data from complete follow-up (quarters one,
two, three and four) were used, there were only a few
itemwise missing values (96.2% of the patients had
complete cost data), except for medication. Hence, for
missing values mean imputation was employed by gener-
ating means of the observed data for the correspondingvariables. Some 16% of medications did not have a valid
pharmaceutical identification number. As unit costs are
only available for medication with a pharmaceutical
identification number, missing data were substituted
based on the documented medication name. If no dos-
age was specified, it was replaced by the patient’s medi-
cation data from other quarters.
Impact of different time periods on measurement of
resource use and cost
The objective of our analysis was to investigate the validity of
incomplete cost data collection in long-term clinical trials,
using data from the KORINNA study. We did not consider
excluding the first and the last quarter of data collection.
The first quarter is important because response rates com-
monly dwindle after the initial assessment as a result of with-
drawal of informed consent or death of study participants
and, in the last period, cost data can be collected efficiently
together with the final assessments. Accordingly, either the
second and/or third quarter were excluded for our study.
For each resource category, mean costs per quarter
and per capita were calculated based on quarterly data
collected from 1 year. The difference between quarterly
costs over the course of time was compared by repeated
measures analysis of variance and Tukey’s multiple com-
parison test. To determine the resource category suitable
for incomplete data collection, mean differences between
quarters were assessed, and assumed inherent recall bias
was considered. In the case of minor recall bias,
complete data collection by extending recall windows
was preferred to incomplete data collection.
For resource categories suitable for incomplete data col-
lection, different kinds of cost calculations were employed.
For extrapolation, the complete values from the following
quarter replaced those from the missing quarter. For
interpolation, the means of the individual values from the
previous quarter and the following quarter were used to
replace the values from the missing quarter.
For each method (extrapolation and interpolation),
three alternative periods of data collection were consid-
ered (Figure 1):
 Alternative 1 (Alt 1): Data collection in the first,
third and fourth quarters and replacing the data
from the second quarter by extrapolating the data
from the third quarter
 Alternative 2 (Alt 2): Data collection in the first,
second and fourth quarters and replacing the data
from the third quarter by extrapolating the data
from the fourth quarter
 Alternative 3 (Alt 3): Data collection in the first and
fourth quarters and replacing the data from the
second and third quarters by extrapolating the data
from the fourth quarter
Figure 1 Overview of incomplete cost collection: methods and
omitted quarters. Alternative 0: complete cost collection.
Alternative 1: extrapolation, omitted quarter 2, replaced by quarter 3.
Alternative 2: extrapolation, omitted quarter 3, replaced by quarter 4.
Alternative 3: extrapolation, omitted quarters 2 and 3, replaced by
quarter 4. Alternative 4: interpolation, omitted quarter 2, replaced by
quarters 1 and 3. Alternative 5: interpolation, omitted quarter 3,
replaced by quarters 2 and 4. Alternative 6: interpolation, omitted
quarters 2 and 3, replaced by quarter 1 and 4.
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third and fourth quarters and replacing the data
from the second quarter by interpolating the data
from the first and third quarters
 Alternative 5 (Alt 5): Data collection in the first,
second and fourth quarters and replacing the data
from the third quarter by interpolating the data
from the second and fourth quarters
 Alternative 6 (Alt 6): Data collection in the first and
fourth quarters and replacing the data from the
second and third quarters by interpolating the data
from the first and fourth quarters
We analysed the influence of the chosen methods on
the accuracy and precision of the total cost estimate in
the following way.
Cost data were calculated as mean costs, and the differ-
ences between complete and incomplete cost data collec-
tion were tested using standard errors and p-values from
paired t-tests. Alternatively, bootstrap resampling was ap-
plied to compute p-values, as there was the possibility that
the differences in costs were skewed. We drew 1000 re-
samples of the data set with replacement.
The effects of alternative intensity of data collection
on precision were studied by comparing the standard
deviation of the respective estimates.
Larger sample sizes are required because of an in-
crease in the variance of the estimate arising from a
shorter period of data collection to keep the power. This
effort must be weighed against the advantages of redu-
cing the data collection costs and the burden on study
participants.
Based on the equations for sample size calculation for
a single outcome and for cost-effectiveness, [34] theimpact of a 1% increase in standard deviation on per-
centage change in sample size, called elasticity (E), was
calculated assuming ceteris paribus, where α, β and the
expected mean difference in costs are not changed The
details of the mathematical calculations are shown in
Appendix 1. The amount of time that would be saved by
collecting data only for a limited period is compared
with the consumed time for additional patients as a re-
sult of the requirements of a larger sample size.
All analyses were performed with SAS (Version 9.2,
SAS-Institute Inc., Cary, NC, USA).
Results
Resource use
Table 2 provides an overview of mean resource use per
patient over 12 months.
Within 1 year, almost all subjects consulted a general
practitioner and ca. 68% consulted a specialist in internal
medicine. On average, patients consulted a physician 21
times a year. All patients were on medication and ingested
on average seven different types of medication at the
same time. Approximately one third of subjects received
physiotherapy about 16 times over the year and attended
the ambulatory clinic at hospital about three times a year.
Forty-five per cent of patients were hospitalised and ad-
mitted for an average of 19 days; about one third of them
had a stay in the intensive care unit of 3.6 days on average.
The majority (59%) of patients received rehabilitation.
About 8% used the outpatient nursing service for 1.3 h
per week, and ca. 11% employed paid household help for
4.8 h per week. Approximately 93% of the patients were
without a care level; about 6% were classed as care level
one, 1% as care level two and none as care level three.
Resource categories suitable for incomplete data
collection
As presented in Table 3, the Tukey test showed that the
costs of inpatient care, rehabilitation and care insurance
benefit levels as a proxy for informal care were signifi-
cantly different between quarters. Usage of physiotherapy,
ambulatory clinic in hospital, outpatient nursing service
and paid household help did not differ significantly be-
tween quarters (Table 3). Costs of physicians were signifi-
cantly lower in the first quarter than in subsequent
quarters. Costs of medication were significantly lower in
the fourth quarter than in the second and third quarters.
Validity of incomplete cost collection
For the cost categories physiotherapy, ambulatory clinic
in hospital, outpatient nursing service, paid household
help, visits to physicians and medications, complete cost
collection was compared with incomplete cost collection
to ascertain which period of data collection could be
omitted.
Table 2 Mean resource use (in number of contacts unless stated otherwise) per patient over 12 months, n=234
Resource category Overall means (SD) Resource use (%) Means of patients using services (SD)
Direct healthcare
General practitioner 13.26 (22.46) 99.37 13.32 (11.45)
Internist 2.16 (2.87) 67.95 3.18 (2.89)
Orthopaedist 1.40 (3.03) 33.33 4.21 (3.99)
Neurologist 0.28 (0.85) 12.38 1.83 (1.36)
Ophthalmologist 1.46 (2.79) 47.15 3.16 (3.39)
Otolaryngologist 0.41 (1.18) 19.66 2.07 (1.94)
Gynaecologist 0.15 (0.58) 9.40 1.64 (1.09)
Dermatologist 1.09 (3.40) 28.63 3.81 (5.51)
Urologist 0.49 (1.38) 18.38 2.67 (2.16)
Other 0.35 (1.33) 14.10 2.49 (2.72)
Sum of physicians 21.06 (14.60) 99.37 21.15 (14.56)
Physiotherapist 5.03 (11.82) 32.05 15.71 (16.44)
Ambulatory clinic in hospital 0.89 (2.75) 32.48 2.74 (4.28)
Inpatient care in stays 0.85 (1.32) 44.87 1.90 (1.37)
Inpatient care/hospital in days (without intensive care unit) 7.89 (16.56) 44.87 17.59 (21.02)
Inpatient care/intensive care unit in days 0.51 (1.74) 14.10 3.64 (3.23)
Inpatient/outpatient rehabilitation in days 13.86 (13.06) 59.40 23.33 (8.09)
Drugs in numbers of medication taken at the same time 6.99 (2.15) 100.00 6.99 (2.15)
Direct non-healthcare
Outpatient nursing service in hours 5.14 (20.98) 7.69 66.81 (40.90)
Paid household help in hours 26.65 (156.40) 10.68 249.48 (423.74)
Informal care (%)
without care level 92.74
Care level one 5.89
Care level two 1.28
Care level three 0
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per capita vs. three alternative periods of incomplete
data collection using extrapolation are illustrated in
Table 4.
All comparisons between complete and incomplete data
collection were not significantly different regarding the p-
values of paired t-tests or the p-values of bootstrapping
the differences in costs. Only drug costs, which averaged
€1315.52 in complete data collection, differed significantly
from incomplete data collection when applying Alt 3
(€1264.26) and Alt 2 (€1291.31). That was to be expected
as the mean costs of the second and third quarters dif-
fered significantly from the mean costs of the fourth quar-
ter (Table 3). By extrapolating the costs of the third
quarter to the second quarter (Alt 1), cost estimation per
year showed no significant differences in means.
Comparisons of complete and incomplete data collec-
tion using interpolation are shown in Table 5.
In the case of incomplete data collection and
interpolation, there were three significant differences incomparison with complete data collection. Drug costs
differed when applying Alt 5 and Alt 6; costs of ambula-
tory clinics in hospital differed when applying Alt 6; the
sum of direct healthcare costs differed when applying
Alt 4. In addition, most of the differences between
complete and incomplete cost collection were larger
than the differences from extrapolation.
Total cost estimation from incomplete data collection
in the case of two data collections was significantly
lower independent of whether extrapolation (3.9%) or
interpolation (4.6%) was used. Interpolation and extrapo-
lation in the case of omitting information from the sec-
ond or third quarter showed no difference.
Table 6 illustrates the precision regarding change in
standard deviation due to incomplete data collection. In
some cases, we found smaller and, in some cases, larger
standard deviations than in complete data collection. For
the sum of direct healthcare costs, the largest increase
was 6.45%, for the sum of direct non-healthcare costs
1.65%, and for the sum altogether 1.65%.
Table 3 Mean costs per patient over different quarters, n=234
Period of time Significant difference
between quartersQuarter 1 Quarter 2 Quarter 3 Quarter 4
Cost category Means (SD) Means (SD) Means (SD) Means (SD)
Direct healthcare costs
Physicians 115.00 (94.54) 139.14 (145.99) 133.33 (119.93) 135.91 (108.93) **1 vs. 2; *1 vs. 4
Physiotherapist 13.57 (49.18) 19.57 (57.59) 16.98 (48.73) 19.10 (57.80)
Ambulatory clinic in hospital 5.17 (20.14) 7.92 (37.99) 14.99 (84.45) 7.75 (32.38)
Inpatient care 1436.71 (4175.58) 1529.02 (4774.59) 723.35 (2851.91) 959.82 (3070.25) *2 vs. 3
Inpatient/outpatient rehabilitation 1238.61 (1085.16) 68.38 (405.57) 24.51 (217.36) 52.56 (365.25) **1 vs. 2, 1 vs. 3, 1 vs. 4
Drugs 325.58 (178.80) 339.94 (203.90) 337.11 (200.37) 312.89 (204.51) **4 vs. 2, 4 vs. 3
Sum of direct healthcare costs 3134.64 (4271.98) 2104.00 (4898.88) 1250.28 (3010.82) 1488.07 (3270.83) **1 vs. 2, 1 vs. 3, 1 vs. 4, 2 vs. 3
Direct non-healthcare costs
Outpatient nursing service 34.67 (162.79) 43.50 (237.95) 38.70 (181.42) 28.56 (151.73)
Paid household help 96.38 (643.07) 111.01 (684.75) 109.03 (626.12) 102.05 (645.84)
Informal care 35.45 (177.98) 43.72 (190.73) 46.47 (194.71) 54.74 (205.98) **1 vs. 4
Sum of direct non-healthcare costs 166.49 (710.79) 198.21 (811.39) 194.20 (729.73) 185.35 (743.39)
Sum of costs 3301.14 (4353.64) 2302.21 (5068.35) 1444.50 (3197.00) 1673.42 (3402.68) **1 vs.2, 1 vs. 3, 1 vs. 4, 2 vs. 3
*p-value of Repeated Measure ANOVA (RMANOVA) Tukey test <0.10.
**p-value of Repeated Measure ANOVA (RMANOVA) Tukey test <0.05.







Alt 0a Alt 1b Alt 2c Alt 3d
Quarter 2 (by 3) Quarter 3 (by 4) Quarter 2 and 3 (by 4)
Cost category mean (SD) mean (SD) mean
difference
(StdErr) mean (SD) mean
difference




Physicians 523.38 (358.27) 517.57 (365.32) 5.81 (9.51) 525.99(370.53) 2.62(6.67) 522.75(377.53) 0.63 (11.91)
Physiotherapist 69.29 (162.63) 66.69 (166.77) 2.61 (3.78) 71.38(178.98) 2.09(3.33) 70.91(202.65) 1.62 (6.73)
Ambulatory clinic
in hospital
35.79 (110.83) 42.89 (181.93) 7.10 (6.00) 28.60(83.44) 7.19(5.30) 28.41(99.47) 7.38 (6.20)
Drugs 1315.52 (707.38) 1312.68 (721.69) 2.84 (7.97) 1291.31(709.17) **24.21(7.54) 1264.26(739.52) **51.26 (16.33)
Sum of direct
healthcare costs





145.44 (593.85) 140.63 (569.41) 4.81 (10.17) 135.29(573.69) 10.15(9.10) 120.36(549.63) 25.08 (19.36)
Paid household help418.46 (2455.42) 416.48 (2433.88)1.97 (20.61) 411.48(2489.45) 6.97(23.66) 402.53(2527.39)15.93 (45.70)
Sum of direct non-
healthcare costs
563.89 (2568.91) 557.11 (2534.07)6.78 (22.98) 546.77(2589.39) 17.12(24.27) 522.89(2598.16) 41.00(46.89)
Sum of costs 2507.88 (2864.38)2496.93 (2827.43)10.96 (28.11) 2464.05(2882.21) 43.83(27.12) 2409.21(2893.05) *98.67(54.67)
*p-value of paired t-test/bootstrapping of differences between complete and incomplete cost collection <0.10.
**p-value of paired t-test/bootstrapping of differences between complete and incomplete cost collection <0.05.
aAlternative 0, complete cost collection.
bAlternative 1, incomplete cost collection, omitted quarter 2, replaced by quarter 3.
cAlternative 2, incomplete cost collection, omitted quarter 3, replaced by quarter 4.
dAlternative 3, incomplete cost collection, omitted quarters 2 and 3, replaced by quarter 4.
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Alt 0a Alt 4b Alt 5c Alt 6d
Quarter 2 (by 1 and 3) Quarter 3 (by 2 and 4) Quarters 2 and 3 (by 1 and 4)








Physicians 523.38 (358.27) 508.40 (343.27) 14.97 (8.58) 527.56 (383.66) 4.19 (7.03) 501.87 (344.89) 21.51(11.62)
Physiotherapist 69.29 (162.63) 64.97 (164.25) 4.31 (3.23) 71.61 (175.50) 2.32 (2.83) 65.37 (185.64) 3.92(5.42)
Ambulatory clinic in
hospital
35.79 (110.83) 37.93 (142.50) 2.14 (3.66) 28.62 (84.32) 7.18 (5.45) 25.88 (76.71) *9.91(5.88)
Drugs 1315.52 (707.38) 1306.92 (701.52) 8.60 (7.23) 1304.79 (707.09) *10.72 (5.75) 1276.92 (692.75) **38.60(12.53)
Sum of direct healthcare
costs





145.44 (593.85) 138.62 (546.78) 6.82 (11.98) 142.76 (608.39) 2.67 (7.35) 126.47 (537.84) 18.97(20.85)
Paid household help 418.46 (2455.42)410.15 (2442.17)8.30 (21.42) 415.96 (2494.90) 2.50 (17.83) 396.86 (2506.58) 21.60(39.02)
Sum of direct non-
healthcare costs
563.89 (2568.91)548.77 (2534.93)15.12 (23.25) 558.73 (2611.32) 5.17 (19.07) 523.33 (2577.07) 40.57(39.89)
Sum of costs 2507.88 (2864.38)2467.00 (2807.64)40.89 (28.29) 2491.31 (2911.74) 16.58 (21.78) 2393.36 (2836.42) **114.5(47.70)
*p-value of paired t-test/bootstrapping of differences between complete and incomplete cost collection <0.10.
**p-value of paired t-test/bootstrapping of differences between complete and incomplete cost collection <0.05.
aAlternative 0, complete cost collection.
bAlternative 4, incomplete cost collection, omitted quarter 2, replaced by quarters 1 and 3.
cAlternative 5, incomplete cost collection, omitted quarter 3, replaced by quarters 2 and 4.
dAlternative 6, incomplete cost collection, omitted quarters 2 and 3, replaced by quarters 1 and 4.
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Incomplete data collection will universally lead to in-
creasing variance of the estimate [13,14]. As the variance
and standard deviation influence sample size calculation,
we modelled the impact of a 1% increase in standard de-





Alt 0a Alt 1b Alt 2c
Cost category (SD) (SD) shift (SD) shift
Sum of direct
healthcare costs
(936.67) (946.22) 1.02 (962.29) 2.74
Sum of direct
non-healthcare costs
(2568.91) (2534.07) −1.36 (2589.39) 0.80 (2
Sum of costs (2864.38) (2827.43) −1.29 (2882.21) 0.62 (2
aAlternative 0, complete cost collection.
bAlternative 1, incomplete cost collection, omitted quarter 2, replaced by quarter 3.
cAlternative 2, incomplete cost collection, omitted quarter 3, replaced by quarter 4.
dAlternative 3, incomplete cost collection, omitted quarters 2 and 3, replaced by qu
eAlternative 4, incomplete cost collection, omitted quarter 2, replaced by quarters 1
fAlternative 5, incomplete cost collection, omitted quarter 3, replaced by quarters 2
gAlternative 6, incomplete cost collection, omitted quarters 2 and 3, replaced by qucalculations are shown in detail in Appendix 1. In the
case of a single outcome (mean difference in costs), the
sample size has to increase by 2% if the standard devi-
ation increases by 1%. In the case of cost-effectiveness
research, the increase in sample size is smaller. If the
standard deviation increases by 1%, the sample size haslete cost collection vs. incomplete cost collection
Incomplete cost collection
Interpolation
Alt 3d Alt 4e Alt 5f Alt 6d
(SD) shift (SD) shift (SD) shift (SD) shift
(997.06) 6.45 (917.58) −2.04 (962.72) 2.78 (936.79) 0.01
598.16) 1.14 (2534.93) −1.32 (2611.32) 1.65 (2577.07) 0.32




arters 1 and 4.
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for cost-effectiveness is lower than for a single outcome.
For the sum of costs, the largest increase was 1.65% in
the case of Alt 5. This would lead to an increase in sam-
ple size of 3.3%, i.e. about 12 patients (from planned 340
to 352).
The necessary time to conduct the quarterly interview
including set-up time was estimated at 0.5 h. The time
for initial and final assessment was estimated at 3 h per
assessment. Incomplete data collection would save be-
tween 170 h (one omitted quarter) and 340 h (two omit-
ted quarters) compared with 84 h, which are still
required for two quarterly interviews and initial and final
assessment for additional patients.Discussion
The aims of this paper were to define suitable resource
categories for incomplete cost data collection, to assess
the validity of alternative strategies, and to point out the
consequences with respect to efficiency.
To determine the resource category suitable for in-
complete data collection, inherent recall bias and mean
differences between quarters should be assessed. In the
case of minor recall bias, Clarke et al. recommend only
the collection of complete data by extending recall win-
dows to ensure that no information is lost and data are
still collected less frequently [13]. Applied to our study,
this means that data collection in the first quarter for
the previous time period of 3 months and in the fourth
quarter for the previous 9 months would be preferable
to incomplete data collection. Recall may be influenced
by the frequency and severity of events, [9,11] so that
less frequent visits and more serious events improve the
memory of resource use.
It became apparent that it is not appropriate to col-
lect data on hospitalisation, rehabilitation and care in-
surance benefits using an incomplete algorithm, but to
account for the entire target period by using longer re-
call periods. These cost categories were both relevantly
different between quarters and the associated events
were less frequent or more serious. Inpatient care indi-
cates a serious event, and patients who had at least one
admission to hospital had on average 1.9 stays per year
(Table 2). As rehabilitation only occurs once a year, it is
a rare event; only five patients reported two stays per
year. Care insurance benefits are granted by care insur-
ance funds, following a lengthy needs assessment
process. For these cases, recall bias is hardly likely.
Bhandari et al. also stated in their review that hospital-
isation is a salient event that may be gathered accur-
ately by applying longer recall periods [9] without an
appreciable increase in recall bias. In addition, patient
reports on hospital stays could be cross-validatedagainst electronic hospital records where these exist.
Clarke et al. recommended trading off recall bias
against information loss, which would be caused by in-
complete data collection. Only if the degree of variation
introduced by incomplete data collection is smaller
than the bias introduced by recall error should a short
time period for cost assessment be preferred [13].
Attention should be paid to the fact that care insur-
ance benefit is a proxy for informal care. If costs in-
curred for informal care are determined by the hours of
care provided by relatives, neighbours or friends, incom-
plete data collection can be used in a similar way to the
collection of outpatient nursing services or paid house-
hold help.
The resource categories physiotherapy, ambulatory
clinic in hospital, medication, consultations (physicians),
outpatient nursing service and paid household help are
deemed to be appropriate for incomplete data collection
for several reasons. First, there is no evidence for differ-
ences in mean costs between the middle quarters (quar-
ters two and three) (Table 3). Second, the portion of
these costs is about 30% of total costs, so that an in-
accuracy of 5% causes a difference of only 1.5%. The
main cost-driving events are hospitalisation and rehabili-
tation accounting for about 70%. Ridyard et al. [8] advise
in their systematic review the balancing of resource use
data collection between the main cost driving events,
the frequency of data collection and the burden on the
researcher. Third, existing differences in mean costs be-
tween quarter one and all the other quarters do not be-
come important in the case of extrapolation. Although
cost data from quarter one are employed in the case of
interpolation, only the sum of direct healthcare costs dif-
fered significantly from complete cost collection (Table 5,
Alt 4) when data were collected three times.
The lower costs in the resource categories physiother-
apy, ambulatory clinic in hospital, medication, consulta-
tions (physicians), outpatient nursing service, and paid
household help in quarter one (Table 3) can be
explained by increased use of rehabilitation and hospital
admissions during this time, which supplants ambulatory
resource use.
Significant differences in mean costs between quarter
four and quarters two or three occur in the case of
medication data (Table 3). This reflects the drug regimen
guidelines [35,36] for the acute coronary syndrome,
which recommend the use of clopidogrel, an antiplatelet
drug, as follow-up treatment for up to 9 months only.
In our analysis, extrapolation turned out to be the
better instrument for replacing the omitted periods,
as quarter one showed consistently lower costs. Data
from quarter one were not used for extrapolation,
but for interpolation. Therefore, mean differences bet-
ween complete and incomplete cost collection from
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interpolation (Tables 4 and 5). Furthermore, medication
data proved to be only suitable for omitting quarter two
and replacing by quarter three, as quarter four is not a
representative quarter.
A comparison of our results is restricted by the lack of
publications of empirical analyses regarding incomplete
data collection. In a study of 174 patients with a
stable chronic disease (fibromyalgia and low back pain),
Goossens et al. showed no significant differences be-
tween multiple time frames of incomplete data collec-
tion [14]. Thus, the authors concluded that, for patients
with chronic diseases, incomplete cost data collection
poses no problem for economic evaluations. They com-
pared the differences in median by Wilcoxon’s signed
rank test but not in arithmetic means, and they did not
distinguish between different cost categories. As the
comparison of means is central to any economic evalu-
ation, non-parametric tests that address differences in
the median and analyses of log-transformed costs that
address differences in the geometric means are not well
suited for this purpose [37]. However, in comparison
with our study, the sample size of 174 participants was
even smaller, which poses severe limitations with regard
to the statistical power of the analysis.
Nevertheless, the authors indicated that, in the case of
acute diseases, randomised clinical trials and chronic
diseases with seasonal effects, the necessary assumptions
of agreement between the different time periods could
not be met. Clarke et al. [13] argued that irregular con-
sumption patterns add estimation error. Seasonal effects
only become important if the time frame of recruitment
is relatively short. If recruitment or the start of the inter-
vention cover a 1-year period, seasonal effects occur for
individuals but not for groups. As the comparison of
arithmetic means between groups is central to any eco-
nomic evaluation, group estimates have to be valid, but
the results for individuals may differ from each other
[15]. Our analysis shows that, in the case of acute myo-
cardial infarction with a 1-year follow-up, several kinds
of resource categories are more appropriate for incom-
plete cost data collection than others. Generalisation of
our findings is limited to the elderly population with
acute diseases, followed by a chronic course associated
with a continuous treatment scheme, as patients with
acute myocardial infarction have similar patterns in the
long-term course of disease and treatment. Applying
incomplete data collection, several points have to be
considered when choosing the method (inter- or ex-
trapolation) and omitting quarters. Only those periods
can be omitted for which it can be assumed that they
are representative of other periods. Equally, only periods
for which one may assume that they represented omitted
periods can be used to replace the omitted periods. Forother studies, the choice of omitted periods may depend
on the disease and the intervention so that these
assumptions must be tested in pilot studies or based on
expert opinions or literature research.
It is important to reduce the burden on study partici-
pants, especially in older participants, by decreasing the
frequency of data collection. Because this can be
achieved by incomplete data collection or extending re-
call windows, one should carefully consider and differen-
tiate which time frame and method of cost data
collection are appropriate for the respective resource
category. As an example, Heinrich et al. [16] assessed re-
source use by employing different time frames for the
respective resource category, whereas Hakkaart-van
Roijen et al. [17] and Kimman et al. [18] did not distin-
guish between different resource categories.
A further problem resulting from incomplete cost col-
lection arises from the withdrawal of informed consent
or death of the study participants, as it can be assumed
that missing data increase because of longer time peri-
ods between data collection. For this reason, we recom-
mend not omitting the first quarter.
Although incomplete cost collection will universally
lead to increasing variance of the estimate, [13,14] we
only found partially larger standard deviations than in
complete data collection. Goossens et al. exclusively
found smaller standard deviations, which they attributed
to random error, and they recommended including
‘more’ patients [14]. To our knowledge, no calculation
concerning increasing standard deviations and sample
size has been published so far. When we assume that a
suitable resource category will be collected incompletely,
our estimate requires a larger sample size of about 3% at
most. Nevertheless, more time would be saved as a re-
sult of incomplete data collection than extra time
required for assessing additional patients. Furthermore,
the burden on study participants and clinical investiga-
tors can be diminished through the economic data col-
lection effort. When conducting economic analysis
alongside clinical trials by means of incomplete data col-
lection, sample size calculation has to be modified.
Conclusions
In economic evaluation, cost data can be collected effi-
ciently by reducing the frequency of data collection. This
can be achieved by data collection for shorter periods,
by implication incomplete data collection, or extending
recall windows so that data are collected completely. To
minimise bias by recall error or information loss, one
has to consider carefully which resource category is suit-
able for incomplete data collection. In our analysis, cost
estimates per year for ambulatory healthcare and non-
healthcare services in terms of three data collections was
as valid and accurate as a four complete data collections.
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sidered that only periods are suitable to be omitted that
have similarity to other periods. The choice of the peri-
ods depends on the disease, treatment guidelines and
the intervention.
When using the method of incomplete data collection
sample, size calculation has to be modified because of
increased variation. This approach is suitable to lower
the burden and costs for the study participants and
investigators in economic evaluation alongside clinical
trials. Further empirical analysis regarding the validity of
incomplete cost collection must be performed in order
to improve the already existing practice of incomplete
cost data collection.
Appendix 1
The equation for sample size calculation for a single out-








where α type I error, the probability of falsely rejecting
the null hypothesis when in fact a true difference exists
zα=2 standardised normal deviate, such for α=0.05, zα=2
(two-sided)=1.96
β type II error, the probability of not rejecting the null
hypothesis when it is false
zβ standardised normal deviate, such for β=0.10, zβ
(one-sided)=1.28
σ2CT variance of the costs in the intervention (trial)
group
σ2CC variance of the costs in the control group
ΔeΕ difference in costs between two groups
To simplify the equation:
zα=2 þ zβ
 2 ¼ a2
σ2CT þ σ2CC



















If the standard deviation increases by 1 percent, the
















σ2ET variance of the effects in the intervention (trial)
group
σ2EC variance of the effects in the control group
σ2CT variance of the costs in the intervention (trial)
group
σ2CC variance of the costs in the control group
ΔeC difference in costs between two groups
ΔeE difference in effects between two groups
Rc„ ceiling“value (maximum acceptable value) of ICER
(incremental cost-effectiveness ratio)
To simplify the equation:
zα=2 þ zβ
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If the standard deviation increases by 1 percent, the
sample size has to increase by
¼ 2 bdþb percent. Since b>0 and d>0, the elasticity for
cost-effectiveness is lower than for a single outcome.
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